BAYRY: Analysis & Opinions

  1. Teva Ends CureTech Collaboration - Analyst Blog

    February 04, 2013
    Teva Pharmaceutical Industries Ltd. (TEVA) recently terminated its collaboration with CureTech Ltd. for the ...
  2. Generics Hurt AZN Results - Analyst Blog

    February 04, 2013
    AstraZeneca's (AZN) fourth-quarter 2012 core earnings of $1.56 per American Depositary Share (ADS) beat the Zacks ...
  3. Roche Grows in 2012 - Analyst Blog

    February 01, 2013
    Roche Holdings Ltd. (RHHBY) recently reported 2012 results. Revenues grew 4% year over year to CHF 45.5 billion ...
  4. Strong 2012 Results at Novo Nordisk - Analyst Blog

    February 01, 2013
    Novo Nordisk (NVO) reported fourth quarter 2012 earnings of $1.83 per American Depository Receipt (ADR), up 21.2% ...
  5. Alnylam's ALN-VSP Data Published - Analyst Blog

    January 31, 2013
    Alnylam Pharmaceuticals Inc. (ALNY) recently announced the publication of complete results from a phase I study on ...
  6. Roche Teams Up With Afraxis - Analyst Blog

    January 30, 2013
    Roche (RHHBY) announced that its wholly owned subsidiary, Genentech, has recently inked a global licensing agreement ...
  7. Acorda Gets US Army Support - Analyst Blog

    January 25, 2013
    Acorda Therapeutics, Inc. (ACOR) recently announced that it has been awarded a research contract worth $2.67 million ...
  8. FDA Approves Novartis' Exjade - Analyst Blog

    January 25, 2013
    Novartis (NVS) recently announced that the US Food and Drug Administration (FDA) has approved Exjade (deferasirox) ...
  9. Disappointing Data from Teva - Analyst Blog

    January 24, 2013
    Teva Pharmaceutical Industries Ltd. (TEVA) recently announced disappointing top-line results from a study evaluating ...
  10. Label Expansion for Roche's Avastin - Analyst Blog

    January 24, 2013
    The US Food and Drug Administration (FDA) recently approved Roche's (RHHBY) Avastin (bevacizumab) in combination ...
  11. Novartis Beats on Revs, EPS In-Line - Analyst Blog

    January 24, 2013
    Swiss pharmaceutical giant Novartis (NVS) reported fourth quarter 2012 earnings per share of 84 cents, up 71% from ...
  12. Earnings Beat at Bristol-Myers - Analyst Blog

    January 24, 2013
    Bristol-Myers Squibb Company's (BMY) fourth quarter 2012 earnings (excluding special items) of 47 cents per share ...
  13. Safety Data on Omeros' OMS302 - Analyst Blog

    January 23, 2013
    Omeros Corporation (OMER) recently announced that it successfully completed the 90-day safety database lock for the ...
  14. Abbott Beats on EPS, Guides In-Line - Analyst Blog

    January 23, 2013
    Abbott Labs (ABT) reported fourth quarter 2012 earnings of $1.51 per share, a penny ahead of the Zacks Consensus ...
  15. Canadian Approval for BMY's Drug - Analyst Blog

    January 16, 2013
    Good news flowed in at Bristol-Myers Squibb (BMY) from Canada when Health Canada, the federal department responsible ...
  16. Upbeat Data on Novartis' Bexsero - Analyst Blog

    January 15, 2013
    As per recent data published in The Lancet, Novartis' (NVS) vaccine candidate, Bexsero (meningococcal group B ...
  17. Data on Novartis' Afinitor - Analyst Blog

    January 14, 2013
    As per recent data published in The Lancet, Novartis' (NVS) cancer drug, Afinitor (everolimus), helped reduce the ...
  18. Bayer to Buy Prophyta - Analyst Blog

    January 11, 2013
    Bayer AG's (BAYRY) Bayer CropScience recently signed an agreement to acquire Prophyta GmbH which develops, produces ...
  19. Catalyst-Filled 2013 for Onyx - Analyst Blog

    January 09, 2013
    Onyx Pharmaceuticals, Inc. (ONXX) recently provided an update on its performance in 2012 and its plans for 2013. ...
  20. Bayer Takes Over Teva Unit - Analyst Blog

    January 07, 2013
    The HealthCare unit of Bayer AG (BAYRY) recently received the necessary regulatory approval from the Federal Trade ...
Marketplace
Trading Center